Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|July 1, 2025
Pulmonology Month in Review: June 2025
Author(s)Victoria Johnson
Fact checked by: Abigail Brooks, MA
June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.
Advertisement
Advertisement
In June, asthma care and respiratory medicine were marked by pivotal updates, including new data reinforcing best practices and highlighting potential therapeutic breakthroughs across multiple respiratory and immune-mediated conditions. This month’s news underscores the importance of optimizing asthma management strategies, advancing biologic therapies for chronic airway diseases, and exploring novel interventions for challenging pulmonary disorders.
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement